– Additional data from pivotal AUGMENT-101 trial in R/R KMT2Ar acute leukemia further highlight revumenib's potential best-in-class profile – – 100% ORR (n=7) and manageable safety profile...

Oral presentation will showcase distinct preclinical profile for potent, selective MALT1 scaffolding inhibitor that is highly differentiated from MALT1 protease inhibitors BOSTON, Nov. 2, 2023...

– Results support axatilimab's promising safety and efficacy profile, and reinforce its potential as a first-in-class CSF-1R monoclonal antibody in chronic graft-versus-host disease – –...

Program participants have exclusive access to the RO element before commercial launch and receive special pricing incentives. BOSTON, Nov. 2, 2023 /PRNewswire/ -- ZwitterCo, the advanced membrane...

CSO Mike Train, CTO Peter Zornio and Power & Water President Bob Yeager will speak at Reuters Energy Transition North America 2023 Conference HOUSTON, Nov. 2, 2023 /PRNewswire/ -- Top executives...